Cervical cancer cells

FDA grants breakthrough therapy designation of new TIL therapy for advanced cervical cancer

In May 2019, the FDA granted breakthrough therapy designation to a tumor-infiltrating lymphocyte (TIL) therapy technology known as LN-145 to treat advanced cervical cancer based on data presented by CCR collaborator Iovance Biotherapeutics. Read more...

Nanoparticles in brain metastases

New strategy for treating brain tumors with mutations in metabolic enzymes

Feb 20, 2019

Cancers with mutations in key metabolic enzymes disrupt oxygen metabolism and cause a buildup of reactive oxygen species in mice. This mutation is found in about 80 percent of grade II/III gliomas, or brain tumors, in humans. By inhibiting the action of a protein that allows cancer cells to survive, investigators have potentially found a new strategy for treating cancers with these mutations. Read more...

Felicia Knaul, Ph.D.

Recap: Grand Rounds with Felicia Knaul, Ph.D.

Feb 19, 2019

Nearly 200 CCR staff attended a special Grand Rounds lecture this month featuring Felicia Knaul, Ph.D., an expert in palliative care. Dr. Knaul, a professor at the Leonard M. Miller School of Medicine and Director of the University of Miami Institute for Advanced Study of the Americas, discussed the unequal access to pain and palliative care around the world, particularly related to morphine for pain relief, and the critical importance of educating providers.The lecture, held February 1, was sponsored by CCR’s Women Scientist Advisors (WSAs).   Read more...

A scanning electron micrograph of a T lymphocyte

Researchers identify a key molecule that enhances T cell-based immunotherapy

Feb 19, 2019

The transcription factor c-Myb plays a critical role in regulating T cell stemness. Researchers showed that increasing expression of this transcription factor in T cells launches a powerful, long-lasting antitumor response in mice.  Read more...

Steve Rosenberg

Steve Rosenberg receives Szent-Györgi Prize for Progress in Cancer Research

Feb 12, 2019

Steve Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, has received the 2019 Szent-Györgi Prize for Progress in Cancer Research. The award recognizes indivuduals with a seminal discovery or a body of work that has resulted in or led toward notable contributions to cancer prevention, diagnosis or treatment, and the discovery has had a lasting impact on the cancer field with a high direct impact of saving lives. Read more...

Steve Rosenberg receives Szent-Györgi Prize for Progress in Cancer Research
HPV cell

Drug successfully treats WHIM syndrome

Feb 12, 2019

Researchers have discovered which genus of human papillomavirus (HPV) is responsible for warts found in patients with WHIM syndrome, a rare autoimmune disease, and determined the drug plerixafor could successfully treat those patients. Read more...

Epstein-Barr virus

Gene mutations in Burkitt lymphoma hint at more effective treatment

Feb 7, 2019

Some cases of Burkitt lymphoma have long been thought to be caused by the Epstein-Barr virus. New research is revealing potential genetic mechanisms for how the virus could contribute to the disease. Read more...

NCI-NIA and Curie-NCI awardees

CCR staff receive NCI-NIA and Curie-NCI awards

Feb 6, 2019

Congratulations to the CCR staff who have been awarded the NCI-NIA Joint Fellowship and the funding opportunity offered through the NCI-NIH and PIC3i Curie.  Read more...

How the oncometabolite fumarate contributes to one type of hereditary kidney cancer

New map of protein interactions hints at the underlying mechanisms of hereditary kidney cancer

Feb 6, 2019

A hereditary form of kidney cancer is characterized by high levels of the metabolite fumarate but how the compound fuels cancer remains a mystery. CCR researchers have mapped the proteins that fumarate interacts with, revealing new links between metabolism and malignancy. Read more...

HCT116 (KRAS-mutant) colorectal cancer cell spheroid.

New insights into mechanisms key to maintaining KRAS-mutant cancer cell survival

Feb 6, 2019

CCR researchers tested nearly 500 different combinations of multi-gene targeting strategies to study the mechanisms that favor the survival of KRAS-mutant colorectal and pancreatic cancer cells over normal cells. This study reveals the previously underappreciated complexity of the signaling network of the KRAS oncogene. Although work remains to be done, the research does suggest potential target combinations for more effective therapeutic interventions. Read more...

Nanoparticles in the brain

Clinical trial studies antitumor effect of sunitinib in central nervous system sarcomas

Feb 4, 2019

A new clinical trial is testing a cancer drug, sunitinib, on recurrent gliosarcoma and previously treated sarcomas of the central nervous system. This drug has been studied in several other types of cancer, where it was able to inhibit factors that help tumors grow and spread. Investigators want to see if sunitinib can have the same antitumor effect on sarcomas and gliosarcoma of the brain and spinal cord. Read more...

Pages